Navigation Links
Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation
Date:12/8/2009

edicines. In fact, more than 3 million jobs -- both direct and indirect -- have been created in the U.S. by America's pharmaceutical research and biotechnology companies. Health care reform, if done right, can help spur even more jobs, improve the quality of care for all Americans and provide a more stable foundation for future generations, according to industry officials.

"The addition of these member companies is a testament to the hard work PhRMA has been doing over the years, which has attracted enormous new talent to our ranks," said David Brennan, Chief Executive Officer, AstraZeneca and PhRMA's Chairman of the Board. "We welcome the new member companies with open arms and look forward to working with them on one of the most important issues of our lifetime -- health care reform."

Cubist President and Chief Executive Officer Michael W. Bonney said, "I am grateful to the PhRMA Board of Directors for electing me to serve among the most highly regarded leaders in our industry. Within the context of the health care reform debate and the current economic struggles and well into the future, I look forward to contributing to the dialogue surrounding our changing industry and our role in shaping that change. PhRMA members have always shown leadership on issues concerning patient care, and I am looking forward to ensuring that those issues remain paramount in the organization's mission."

"As a growing biopharmaceutical company, membership in PhRMA will enable OSI Pharmaceuticals to expand our ability to fully engage in important policy discussions at the federal, state and global level," stated Colin Goddard, Ph.D., Chief Executive Officer at OSI Pharmaceuticals, Inc. "We look forward to collaborating with other PhRMA members to ensure companies like OSI can continue to flourish in providing important life changing therapies to patients around the world."

"Advocacy organizations are operating in a very difficult environme
'/>"/>

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
2. Seven-Year Neck Pain Study Sheds Light on Best Care
3. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
4. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
5. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
11. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 3, ... therapeutics for the treatment of cancer, today announced ... team. Debanjan Ray , who ... and alliance management, has been promoted to senior ... to joining CytomX, Mr. Ray held positions as ...
(Date:8/3/2015)... PARK, N.J. , Aug. 3, 2015 ... and secondary endpoints in a phase III study (COMPOSE ... adult patients with chronic non-cancer pain. Naldemedine is an ... is the third Phase III trial in which naldemedine ... Study results showed that a 0.2 mg tablet of ...
(Date:8/3/2015)... Aug. 3, 2015  Encision Inc. (PK:ECIA), a medical ... stray electrosurgical burns in minimally invasive surgery, today announced ... ended June 30, 2015. The Company posted ... net loss of $213 thousand, or $(0.02) per share. ... for a net loss of $202 thousand, or $(0.02) ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... on the development of zinc finger DNA-binding protein (ZFP) Therapeutics® ... collaborators at the 14th Annual Meeting of the American Society ... in Seattle from May 18-21, 2011. "Sangamo,s ...
... Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX ), ... clinical data highlighting the safety profile of EXPAREL™ ... the 2011 International Anesthesia Research Society (IARS) Annual ... Comprehensive, program-wide safety data for EXPAREL will be ...
Cached Medicine Technology:Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 2Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 3Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 4Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 2Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 3Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 4Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 5
(Date:8/3/2015)... ... August 03, 2015 , ... According to an opinion piece published July ... diet leads to one pound of weight loss may not be accurate. While this system ... to one pound of fat varies – based both on the individual and at what ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to ... related claims in which a claimant alleged to have suffered an arterial blood clot ... birth control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate ... BESLER Consulting's campaign for the launch of their Readmissions Analytics product was selected ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... R&D services to contract research organisations (CROs) for a slew of benefits, allowing ... global research and operations, boost quality with cost-effective utilisation of resources, get access ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... notes that while an overwhelming number of Hispanics believe people can positively ... overwhelming 70 percent of participants queried said making diet changes was important. Far ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... ... the highest honors in the industry. , ... (PRWEB) March 8, 2010 -- The Sturge-Weber Foundation honored renowned dermatologist Dr. David J. Goldberg with ... 2010. Dr. Goldberg is a pioneer in the field of dermatology and director ...
... ... ... ... ...
... developed a new mathematical approach to analyze molecular data ... when combined with well-established techniques, readily identifies changes in ... potential to distinguish between health and disease states. ... Ph.D., of Stanford University, Calif., the team of investigators ...
... Doctors should do more to explain test results, researchers find ... do a better job of explaining genomic test results to ... which analyzes 21 genes in breast tumors removed during surgery ... can help guide decisions about the use of chemotherapy in ...
... , ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:The Sturge-Weber Foundation Honors Dr. David J. Goldberg 2Health News:The Sturge-Weber Foundation Honors Dr. David J. Goldberg 3Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 2Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 3Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 4Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 5Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 6Health News:New approach to immune cell analysis seen as first step to better distinguish health and disease 2Health News:New approach to immune cell analysis seen as first step to better distinguish health and disease 3Health News:Breast Cancer Patients Often Confused by Genomic Testing 2Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 2Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 3Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 4Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 5Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 2Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 3Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 4Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: